- EBIT Performance: Mycronic’s EBIT for the fourth quarter reached SEK 527 million, surpassing the estimated SEK 378.3 million.
- Net Sales Achievement: The company reported net sales of SEK 2.06 billion, which exceeded the expected SEK 1.78 billion.
- Order Intake: Orders for the period were robust, amounting to SEK 2.38 billion.
- Analyst Ratings: The investment community holds a positive outlook with three buy ratings and one hold rating, while there are no sell ratings.
A look at Mycronic AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Mycronic AB seems to have a promising long-term outlook. With a strong growth score of 4 and high resilience and momentum scores of 5, the company appears well-positioned for future success. The growth score suggests that Mycronic AB has good potential for expanding its business operations. Furthermore, the high resilience and momentum scores indicate that the company is sturdy and has a positive trend in the market. Although the value and dividend scores are more modest at 2, the overall outlook for Mycronic AB appears positive.
Mycronic AB, a computer technology company, is actively involved in developing, manufacturing, and marketing laser writers for microlithography, SMT placement machines, and stencil-free printers within the electronics industry. With a strong focus on innovation and cutting-edge technology, coupled with the favorable Smartkarma Smart Scores in growth, resilience, and momentum, Mycronic AB seems poised for long-term success in its industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
